EVK:XETREvonik Industries AG Analysis
Data as of 2026-05-21 - not real-time
€16.99
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Evonik (EVK) trades just above its identified support of €16.99 and below the 20‑day SMA of €17.63, indicating short‑term price pressure. The bullish trend flag is tempered by a bearish MACD histogram and a neutral RSI of 40, suggesting limited upside momentum in the near term. Volume is rising, which adds some confidence to the price holding its support, but the high P/E of ~50 and a negative revenue growth of 9.3% raise concerns about earnings sustainability. The dividend yield looks attractive at 5.9%, yet the payout ratio exceeds 300%, making the dividend financially untenable.
From a valuation perspective, the DCF‑derived fair value of €23.68 is well above the current price, implying a substantial upside potential if the company can improve cash generation and curb debt (DE/Equity ~46%). However, the sector’s inherent regulatory exposure, combined with a 30‑day volatility of 20.6% and modest beta, points to a medium‑to‑high risk profile. Investors should weigh the short‑term technical weakness against the longer‑term undervaluation and sector fundamentals.
From a valuation perspective, the DCF‑derived fair value of €23.68 is well above the current price, implying a substantial upside potential if the company can improve cash generation and curb debt (DE/Equity ~46%). However, the sector’s inherent regulatory exposure, combined with a 30‑day volatility of 20.6% and modest beta, points to a medium‑to‑high risk profile. Investors should weigh the short‑term technical weakness against the longer‑term undervaluation and sector fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near technical support
- Bearish MACD divergence
- Increasing volume but neutral RSI
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- DCF upside to €23.68
- Weak earnings and high payout ratio
- Sector stability with moderate regulatory risk
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant undervaluation versus fair value
- Potential for cash‑flow improvement and debt reduction
- Specialty chemicals demand resilience
Key Metrics & Analysis
Financial Health
Revenue Growth-9.30%
Profit Margin1.14%
P/E Ratio50.0
ROE1.94%
ROA2.70%
Debt/Equity46.36
P/B Ratio1.0
Op. Cash Flow€1.5B
Free Cash Flow€1.1B
Technical Analysis
TrendBullish
RSI40.1
Support€16.99
Resistance€17.93
MA 20€17.63
MA 50€16.43
MA 200€15.11
MACDBearish
VolumeIncreasing
Fear & Greed Index91.5
Valuation
Fair Value€23.68
GradeUndervalued
TypeValue
Dividend Yield5.89%
Risk Assessment
Beta-0.08
Volatility20.57%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.